Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Amarin Corp Plc\uk (AMRN): which funds own it

Health Care →(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow AMRN for free
Share

Sections with a free account

1 concentrated manager holds it; combined they have held more shares for 2 quarters in a row (1 added, 0 trimmed). Its median weight in those portfolios is 0.5%.

Who owns Amarin Corp Plc\uk?

Amarin Corp Plc\uk trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. As of Jun 30, 2026, the largest ADR holders reported on Form 13F were Sarissa Capital Management (1.7 million ADRs), Acadian Asset Management (720,984 ADRs) and Kynam Capital Management (532,982 ADRs).

Which institutions hold the most Amarin Corp Plc\uk shares?

Per Form 13F filings as of Jun 30, 2026, in ADRs:

  1. 1. Sarissa Capital Management: 1.7 million ADRs
  2. 2. Acadian Asset Management: 720,984 ADRs
  3. 3. Kynam Capital Management: 532,982 ADRs
  4. 4. Morgan Stanley: 223,617 ADRs
  5. 5. Waterfront Wealth: 213,949 ADRs
  6. 6. Brooklands Fund Management: 177,325 ADRs
  7. 7. Eversept Partners: 145,296 ADRs
  8. 8. Millennium Management: 115,808 ADRs
  9. 9. Two Sigma Investments: 100,511 ADRs
  10. 10. Citadel Advisors: 95,364 ADRs

Sources:All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since December 2024: a holder above 5% that has not filed since then does not appear here.

Amarin Corp Plc\uk revenue

Amarin Corp Plc\uk reported annual revenue of $213.6 million for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).

Concentrated managers
1
All 13F: 80
Consensus
—
No score: it needs 5 or more concentrated managers
Price at Jun 30, 2026 (per 13F)
$15.94
+10.2% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (1 → 1): 0 opened · 0 exited = 0

Net flow in the quarter: +$966K (+61 K shares) · bought $966K and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Accumulation: combined they have held more shares for 2 quarters in a row (1 added, 0 trimmed). It is the combined share count of those still holding it: one large buyer can outweigh many who trimmed.

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of AMRN (all 13F filers)

  • Sarissa Capital Management1.7 MInvestment firm · 0.40% of the company0
  • Acadian Asset Management721 KQuant or multi-manager · 0.17% of the company+84 K
  • Kynam Capital Managementconcentrated533 KInvestment firm · 0.13% of the company+61 K
  • Morgan Stanley224 KBank or trading desk · 0.05% of the company−70 K
  • Waterfront Wealth214 KWealth adviser · 0.05% of the company+11 K
  • Brooklands Fund Management177 KType not verified · 0.04% of the company+177 K
  • Eversept Partners145 KInvestment firm · 0.03% of the company−2,419
  • Millennium Management116 KQuant or multi-manager · 0.03% of the company−185 K
  • Two Sigma Investments101 KQuant or multi-manager · 0.02% of the company−7,031
  • Citadel Advisors95 KQuant or multi-manager · 0.02% of the company+15 K

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Fundamentals

12-month figures to Sep 30, 2026 · balance sheet as of Sep 30, 2026.

Profitability
Operating margin
-18.2%
Net margin
-10.9%
ROE
-4.3%
Growth
Revenue (TTM)
$176M
Revenue growth
-22.3%
Net income (TTM)
$-19.1M
Balance sheet
Net debt / EBITDA
—
Free cash flow (TTM)
—
Quality vs sector
—

This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2025: 415.0 M

415.0 M0
20162025
1 year
+1.0%
3 years
+3.4%
5 years
+8.7%
Buybacks (FY 2025)
no data
Share issuance
no data
Stock-based compensation
$13.9M6.5% of revenue
Dividends paid
no data

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
no datanot calculated with negative net income
Interest coverage (operating income ÷ interest)
−7,167 timesnegative operating income
Debt due within 12 months
no data

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

This list may be incomplete: we hold 13D and 13G filings made since December 2024. A holder above 5% that has not filed anything since then is not shown here.

No recent filings.

Flagged material events (8-K)

  • Mar 27, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow AMRN for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow AMRN